Cenobamate Review Shows Strong Seizure Control Results

What was studied

This paper is a review article about cenobamate, a seizure medicine. It summarizes what is known about the drug's pharmacology, possible mechanisms of action, efficacy, safety, and the seizure or epilepsy types it has been used for.

The review mainly covers studies in adults with focal seizures, because cenobamate was approved in the U.S. in 2019 for adults with focal (partial-onset) seizures. It also includes a more recent randomized, controlled study in people ages 12 to 65 with primary generalized tonic-clonic seizures, along with animal studies and reports published after the drug came into wider use.

What they found

The review describes cenobamate as an antiseizure medicine with two possible mechanisms that may contribute additively or synergistically: selective inhibition of persistent sodium currents while sparing transient sodium currents, and augmentation of GABA-mediated tonic currents. In animal studies, it showed broad-spectrum antiseizure activity in rodent models of generalized and focal seizures.

In 3 randomized, placebo-controlled trials in adults with focal seizures, median 28-day seizure frequency reductions ranged from 36.0% to 100% at doses of 100 to 400 mg/day. In the maintenance phases of these trials, 21.0% to 52.4% of patients on higher doses were reported to be seizure-free. In a later randomized, controlled study of patients ages 12 to 65 with primary generalized tonic-clonic seizures, 43% of people taking cenobamate were seizure-free compared with 20% taking placebo.

The review also says that open-label extension, postmarketing, and observational studies have consistently reported high seizure-free rates, including among some treatment-resistant patients. Reported seizure freedom was higher in some studies of people with milder epilepsy or epilepsy of shorter duration.

Limits of the evidence

This is a review, not a single new experiment, so its conclusions depend on the quality and design of the studies it discusses. The abstract does not give much detail about side effects, how many people were in each study, how long follow-up lasted, or how patients were selected.

Some of the strongest numbers mentioned in the abstract come from open-label extension, postmarketing, and observational studies, which are generally less rigorous than randomized, placebo-controlled trials. The seizure-free rates reported in those studies may not apply to every patient. Because cenobamate was approved for adults with focal seizures, the evidence summarized here is strongest for that group, while evidence for other seizure types and younger ages is more limited in this abstract.

For families and caregivers

For families, this review suggests that cenobamate may be an important option for some people whose seizures are not fully controlled, especially adults with focal seizures. The results described here are encouraging because some studies reported large seizure reductions and seizure freedom in a portion of patients.

At the same time, this review does not show that everyone will respond this well, and the abstract gives limited detail about safety. Families may want to know that the evidence summarized here is strongest for adult focal epilepsy, while evidence for other seizure types or younger ages is still more limited in this abstract.

What to watch next

Useful next steps would include more randomized controlled trials in different age groups and seizure types, along with clearer long-term safety data.

Terms in this summary

focal seizures

Seizures that start in one area of the brain.

placebo-controlled trial

A study that compares a real treatment with an inactive treatment to see if the drug truly helps.

randomized

People are assigned by chance to different study groups, which helps make comparisons fairer.

GABA

A brain chemical that helps calm nerve activity.

sodium currents

Electrical flows in nerve cells that help signals travel; changing them can affect seizures.

treatment-resistant epilepsy

Epilepsy that is still not controlled after trying standard seizure medicines.

primary generalized tonic-clonic seizures

Seizures that involve both sides of the brain from the start and usually cause stiffening and jerking.

observational study

A study where researchers watch what happens in real-world care without randomly assigning treatment.